Clinical trials: Corneal Dystrophy
Corneal Endothelial Dystrophy, Corneal Edema
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty…
- Trial name
- NCT05136443
- Testing
- loteprednol etabonate 0.25% ophthalmic suspension
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Price Vision Group
Fuchs' Dystrophy, Bullous Keratopathy
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery.
- Trial name
- NCT01448213
- Testing
- Prednisolone acetate, Fluorometholone
- Where
- 2 sites in United States, Germany
- Volunteers
- 264 people
- Sponsor
- Price Vision Group
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
- Trial name
- NCT03248037
- Testing
- Netarsudil
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Cornea Research Foundation of America
Corneal Disease, Fuch's Dystrophy
Cornea Donor Study
The Cornea Donor Study (CDS) was designed as a prospective cohort study with the following objectives: To determine whether the graft-failure rate over a 5-year follow-up period following corneal transplantation is the same when…
- Conditions
- Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
- Trial name
- CDS (NCT00006411)
- Testing
- corneas assigned by donor age group
- Where
- United States
- Volunteers
- 1,090 people
- Sponsor
- National Eye Institute (NEI)
Corneal Dystrophy, Epithelial Basement Membrane
Optimizing the Ocular Surface Prior to Cataract Surgery
Prospective study to evaluate the efficacy of using self-retained cryopreserved amniotic membrane after debridement in treating Epithelial Base Membrane Dystrophy (EBMD) to optimize the ocular surface integrity and intraocular…
- Trial name
- NCT02766907
- Testing
- cryopreserved amniotic membrane
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- BioTissue Holdings, Inc
Fuchs' Endothelial Corneal Dystrophy
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
- Trial name
- NCT04250207
- Testing
- K-321 Solution
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Kowa Research Institute, Inc.
Fuchs Endothelial Corneal Dystrophy
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD).
- Trial name
- PHANTOM (NCT05376176)
- Testing
- STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 86 people
- Sponsor
- Santen Inc.
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
- Conditions
- Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
- Trial name
- INTREPID (NCT04520321)
- Testing
- TTHX1114(NM141)
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Trefoil Therapeutics, Inc.
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells through 1 year following Descemet membrane endothelial keratoplasty (DMEK).
- Trial name
- DEKS (NCT05134480)
- Testing
- Descemet membrane endothelial keratoplasty
- Where
- 2 sites in United States
- Volunteers
- 1,097 people
- Sponsor
- Case Western Reserve University
Fuchs Endothelial Dystrophy
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could…
- Trial name
- NCT04051463
- Testing
- Netarsudil Ophthalmic Solution
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Price Vision Group
Fuchs Endothelial Dystrophy, Corneal Edema
Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
Descemet's stripping with endothelial keratoplasty (DSEK) is a cornea-sparing transplant technique that replaces only the diseased endothelial cell layer of the patient's cornea.
- Trial name
- NCT00624221
- Testing
- Descemet's stripping endothelial keratoplasty
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cornea Research Foundation of America
Corneal Edema
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
- Trial name
- Fuchs (NCT04498169)
- Testing
- Netarsudil Ophthalmic
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aerie Pharmaceuticals
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Fuchs' Endothelial Dystrophy
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central…
- Trial name
- NCT03971357
- Testing
- Netarsudil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Price Vision Group
Fuchs' Corneal Endothelial Dystrophy (FCED)
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal…
- Trial name
- SPIFD-101 (NCT02653391)
- Testing
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stealth BioTherapeutics Inc.
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
The purpose of this study is to report the early clinical outcomes in patients undergoing Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) for corneal edema secondary to corneal endothelial cell dysfunction, and to…
- Trial name
- DSAEK (NCT00744796)
- Testing
- DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multicentric Castleman Disease
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial.
- Trial name
- NCT04585893
- Testing
- Rituximab, Etoposide
- Where
- Malawi
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Fuchs' Dystrophy, Corneal Edema
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Graft rejection has traditionally been one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used for an extended period after transplant surgery.
- Trial name
- NCT01853696
- Testing
- loteprednol etabonate, prednisolone acetate 1%
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Cornea Research Foundation of America